IL10 and type 2 diabetes mellitus: Additionally, a study conducted on human patients with a diagnosis of type 2 diabetes mellitus (T2DM) treated with sitagliptina, a linagliptin analog [69], for approximately 48 weeks, showed significant increases in IL-10 levels in circulating monocytes in peripheral blood [108].